Skip to main
  1. Stocks
  2. Cerenome Inc
  3. Forecast
CNSY

Cerenome Inc (CNSY) Stock Forecast & Price Target

Cerenome Inc (CNSY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cerenome is attractive fundamentally because it combines a differentiated CNS oncology pipeline with a commercial diagnostic platform, giving investors both clinical optionality and near-term revenue potential. REYOBIQ’s updated interim data showed clean safety with no DLTs in the multi-dose study, while CNSide generated first revenues of $722K from 222 tests, reached 26 institutions and 45 providers, and achieved payer coverage of about 190M lives. With LM and GBM toplines expected around mid-2027, CNSide projected to scale further, and cash plus debt support into 2028, the risk-reward profile appears compelling despite reimbursement and clinical execution risks.

Bears say

Cerenome is viewed negatively because its operating performance remains weak, with Q3 revenue of $722K only in line with consensus but a net loss of $1.14 per share versus the expected $0.98 loss, while Q2 2026 revenue of $0.4 million and EPS of $(1.31) both missed estimates materially. The company’s $4.9M cash balance at the end of Q3 may last into 1Q27, but reliance on ATM sales and the 3i facility underscores a significant financing overhang that can pressure the stock. Reflecting softer commercialization and ongoing losses, 2026 revenue estimates were cut to $3.0 million from $4.0 million and EPS to $(4.40) from $(3.77), signaling limited near-term fundamental improvement.

Cerenome Inc (CNSY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cerenome Inc and is not a guaranteed prediction by Public.com or investment advice.

Cerenome Inc (CNSY) Analyst Forecast & Price Prediction

Get the latest Cerenome Inc (CNSY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cerenome Inc (CNSY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cerenome Inc (CNSY) Forecast

Analysts have given Cerenome Inc (CNSY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cerenome Inc (CNSY) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cerenome Inc (CNSY)


Cerenome Inc (CNSY) Analyst Forecast & Price Prediction

Get the latest Cerenome Inc (CNSY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cerenome Inc (CNSY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CNSY stock data and trends